Raloxifene inhibits hepatitis C virus infection and replication

Postmenopausal women with chronic hepatitis C exhibited a poor response to interferon (IFN) therapy compared to premenopausal women. Osteoporosis is the typical complication that occurs in postmenopausal women. Recently, it was reported that an osteoporotic reagent, vitamin D3, exhibited anti-hepati...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Midori, Ikeda, Masanori, Mori, Kyoko, Yano, Masahiko, Ariumi, Yasuo, Dansako, Hiromichi, Wakita, Takaji, Kato, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642163/
https://www.ncbi.nlm.nih.gov/pubmed/23650611
http://dx.doi.org/10.1016/j.fob.2012.08.003
_version_ 1782268114021384192
author Takeda, Midori
Ikeda, Masanori
Mori, Kyoko
Yano, Masahiko
Ariumi, Yasuo
Dansako, Hiromichi
Wakita, Takaji
Kato, Nobuyuki
author_facet Takeda, Midori
Ikeda, Masanori
Mori, Kyoko
Yano, Masahiko
Ariumi, Yasuo
Dansako, Hiromichi
Wakita, Takaji
Kato, Nobuyuki
author_sort Takeda, Midori
collection PubMed
description Postmenopausal women with chronic hepatitis C exhibited a poor response to interferon (IFN) therapy compared to premenopausal women. Osteoporosis is the typical complication that occurs in postmenopausal women. Recently, it was reported that an osteoporotic reagent, vitamin D3, exhibited anti-hepatitis C virus (HCV) activity. Therefore, we investigated whether or not another osteoporotic reagent, raloxifene, would exhibit anti-HCV activity in cell culture systems. Here, we demonstrated that raloxifene inhibited HCV RNA replication in genotype 1b and infection in genotype 2a. Raloxifene enhanced the anti-HCV activity of IFN-α. These results suggest a link between the molecular biology of osteoporosis and the HCV life cycle.
format Online
Article
Text
id pubmed-3642163
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-36421632013-05-06 Raloxifene inhibits hepatitis C virus infection and replication Takeda, Midori Ikeda, Masanori Mori, Kyoko Yano, Masahiko Ariumi, Yasuo Dansako, Hiromichi Wakita, Takaji Kato, Nobuyuki FEBS Open Bio Article Postmenopausal women with chronic hepatitis C exhibited a poor response to interferon (IFN) therapy compared to premenopausal women. Osteoporosis is the typical complication that occurs in postmenopausal women. Recently, it was reported that an osteoporotic reagent, vitamin D3, exhibited anti-hepatitis C virus (HCV) activity. Therefore, we investigated whether or not another osteoporotic reagent, raloxifene, would exhibit anti-HCV activity in cell culture systems. Here, we demonstrated that raloxifene inhibited HCV RNA replication in genotype 1b and infection in genotype 2a. Raloxifene enhanced the anti-HCV activity of IFN-α. These results suggest a link between the molecular biology of osteoporosis and the HCV life cycle. Elsevier 2012-08-22 /pmc/articles/PMC3642163/ /pubmed/23650611 http://dx.doi.org/10.1016/j.fob.2012.08.003 Text en © 2012 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non- commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Takeda, Midori
Ikeda, Masanori
Mori, Kyoko
Yano, Masahiko
Ariumi, Yasuo
Dansako, Hiromichi
Wakita, Takaji
Kato, Nobuyuki
Raloxifene inhibits hepatitis C virus infection and replication
title Raloxifene inhibits hepatitis C virus infection and replication
title_full Raloxifene inhibits hepatitis C virus infection and replication
title_fullStr Raloxifene inhibits hepatitis C virus infection and replication
title_full_unstemmed Raloxifene inhibits hepatitis C virus infection and replication
title_short Raloxifene inhibits hepatitis C virus infection and replication
title_sort raloxifene inhibits hepatitis c virus infection and replication
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642163/
https://www.ncbi.nlm.nih.gov/pubmed/23650611
http://dx.doi.org/10.1016/j.fob.2012.08.003
work_keys_str_mv AT takedamidori raloxifeneinhibitshepatitiscvirusinfectionandreplication
AT ikedamasanori raloxifeneinhibitshepatitiscvirusinfectionandreplication
AT morikyoko raloxifeneinhibitshepatitiscvirusinfectionandreplication
AT yanomasahiko raloxifeneinhibitshepatitiscvirusinfectionandreplication
AT ariumiyasuo raloxifeneinhibitshepatitiscvirusinfectionandreplication
AT dansakohiromichi raloxifeneinhibitshepatitiscvirusinfectionandreplication
AT wakitatakaji raloxifeneinhibitshepatitiscvirusinfectionandreplication
AT katonobuyuki raloxifeneinhibitshepatitiscvirusinfectionandreplication

Ejemplares similares